Matt Jenkins



Matt is responsible for transaction origination and execution, portfolio company value creation initiatives, investment policy, and investor relations.

Prior to joining QHP Capital, Mr. Jenkins established and led the private equity investment portfolio at RTI International where he focused on precision medicine, clinical research, real world evidence, genomics, population healthcare, and consumer-oriented diagnostics. Matt led and managed investments including BioIQ (acquired by Let’s Get Checked), PierianDx, Seven Bridges Genomics, Clinical Ink, and SPH Analytics (acquired by Press Gainey).

Matt served as SVP, Strategy & Corporate Development and General Manager at M*Modal a healthcare technology firm (acquired by 3M) and was a Corporate Vice President at Allscripts (MDRX), a digital healthcare technology organization serving providers, payers, and biopharma clients with annual revenues exceeding $1.4 billion where Matt led corporate development (M&A) and held executive roles in strategic planning, product marketing, and business development.

Prior to Allscripts, Mr. Jenkins was one of the three founding members of Cellective Therapeutics (acquired by Medimmune), a biopharmaceutical firm focused on the development of monoclonal antibodies (MAbs) that target B-cell antigens to treat autoimmune diseases and lymphomas.  Matt also worked at one of the most active venture capital firms in the Southeast where he focused on technology and life science equity investments.

Matt began his career at Ernst & Young, where as a Consulting Manager he helped grow the Washington, DC practice by leading and delivering performance improvement and strategic advisory engagements for technology sector clients.


  • Bachelor of Science from UNC-Chapel Hill
  • MBA from the Kenan-Flagler Business School at UNC-Chapel Hill